



به نام خدای بخشنايندۀ مهربان

In the name of Allah, the Beneficent, the Merciful.




Potential and Challenges of Stem Cell Therapy in Infertility Treatment

Somaieh Kazemnejad, Ph.D.

Clinical Embryologist
Director of Tissue Engineering and Regenerative
Medicine Department,
Avicenna Research Institute, ACECR, Tehran

Infertility statistics 2021: How many couples are affected by infertility?

- An estimated 15% of couples will have trouble conceiving. (UCLA Health, 2020)



Causes of infertility

- Tubal factor – 13%,
- Ovulatory dysfunction – 15%,
- Diminished ovarian reserve – 31%,
- Endometriosis – 8%,
- Uterine factor – 6%,
- Male factor – 33%,
- Other factors – 17%,
- Unknown factor – 13%.

Types of infertility treatment

- 4%: medications only
- 21%: IUI,
- 53%: IVF
- 22%: did not pursue cycle-based treatment.

(Fertility and Sterility, 2011)

REALITY CHECK

IVF SUCCESS RATES

IVF with own eggs woman age 35-40*

pregnancy rate

per embryo
transfer

46%

VS

per started
IVF cycle

31%

live birth

per embryo
transfer

37%

VS


per started
IVF cycle

25%

EggDonationFriends.com

*Based on: CDC - 2015 - Assisted Reproductive Technology,
Fertility Clinic Success Rates Report

IVF Success Rate After 3 Cycles By Disease Type




Source: SART




the only hope



What do stem cells make as interesting?




Stem cells in all careers of life



Single Cell Embryo

Totipotent



5-7 Day Embryo

Embryonic Stem (ES) Cells
Pluripotent



Infant





Adult

"Adult" Stem Cells
Multipotent


Cord Blood Stem Cells
Placental Stem Cells
Multipotent

Locations of **Somatic Stem Cells** in the body







Caplan, Al. 2007. Adult Mesenchymal Stem Cells for Tissue Engineering Versus Regenerative Medicine; Journal of Cellular Physiology



Zhang et al. Stem Cell Report.2021

Stem cells are different based on plasticity





Mesenchymal stem cell sources

Bone marrow

Peripheral blood

Umbilical cord blood

Menstrual blood

Adipose tissue




Amniotic fluid

Endometrium



Placenta

Dental pulp

Cord (Wharton's Jelly)




Characteristics of Mesenchymal stem cells




The mesenchymal markers


- ❖ CD29 (Adhesion molecule on mesenchymal and hepatic stem cells)
- ❖ CD44 (Hyaluronic acid receptor)
- ❖ CD73 (Ecto-5'-nucleotidase, involved in migration of MSC)
- ❖ CD105 (Marker of tissue and MSC)
- ❖ CD106 (Vascular cell adhesion molecule-1)
- ❖ CD146 (Melanoma Cell associated Adhesion Molecule)
- ❖ CD90 (Fibroblast marker)
- ❖ STRO1 (MSCs marker)

Potential uses of **Stem cells**



Proposed mechanisms underlying efficacy of stem cell therapy





Stem cell therapy based on donor type

Autologous transplantation


- they are potentially much more expensive to manufacture
- greater inherited variability



Allogenic transplantation

the potential immunorejection is of concern.

Global Stem Cell Therapy Market Dynamics

**Global Stem Cell Therapy Market, by Treatments
2019-2026 (USD Bn)**







Hypothalamic amenorrhea




Pituitary adenoma

Stem cell therapy
-Bone marrow MSC
-Adipose tissue MSC
-Endometrial MSC
-Menstrual blood MSC
-Ovarian stem cell

Stem cell therapy
-Bone marrow MSC
-Adipose tissue MSC
-Spermatogonial stem cell



Kallmann syndrome
Hemochromatosis



The potential of stem cell therapy in infertility





Table 1. Clinical trials related stem cell therapy performed or underway for improvement of infertility.

Trial Identifier	Est. # of Subjects	Status	Site	Conditions	Interventions	Outcome of Trial
NCT04706312	12	Not yet recruiting	Nanjing Medical University	Diminished Ovarian Response	Human Amniotic Mesenchymal Stem Cells (HamsCs) Transplantation	No results posted
NCT04676269	40	Recruiting	Indonesia University	Thin Endometrium Infertile Patients	Amnion Bilayer and Stem Cell Combination Therapy	No results posted
NCT03207412	20	Unknown	Chongqing Medical University, China	Premature Ovarian Failure	Human Amniotic Epithelial Cells	No results posted
NCT02696889	3	Active	University of Illinois at Chicago	Primary Ovarian Insufficiency, Low Ovarian Reserve	Autologous Stem Cell Therapy	Report of 2 cases revealed a significant improvement in clinical features related to POI. There was an increase in size as well as estrogen production in the MSC engrafted ovary [174]
NCT02713854	240	Recruiting	The University of Hong Kong	Subfertility	Human Embryonic Stem-Cell-Derived Trophoblastic Spheroid (Bap-Eb) as a Predictive Tool Procedure: Collagen Scaffold	No results posted
NCT03592849	50	Enrolling by invitation	Nanjing Drum Tower Hospital, China	Infertile Women with Thin Endometrium or Endometrial Scarring	Loaded with Umbilical-Cord-Derived Mesenchymal Stem Cells Therapy	No results posted
NCT03166189	46	Completed	D.O. Ott Research Institute of Obstetrics, Gynecology, Russian Federation	Infertility of Uterine Origin Asherman Syndrome	Biological: Bone Marrow-Derived Msc and Hrt Other: Hormonal Replacement Therapy	No Results Posted
Saha et al. Cells 2021, 10(7), 1613						Phase 1 trial revealed that transplantation of clinical


Trial Identifier	Est. # of Subjects	Status	Site	Conditions	Interventions	Outcome of Trial
NCT02313415	26	Completed	Gynecology, Russian Federation Nanjing Drum Tower Hospital, China	Infertility with Intrauterine Adhesions	Replacement therapy Procedure: Umbilical Cord Mesenchymal Stem Cells	Phase 1 trial revealed that transplantation of clinical grade human UC MSC could improve the proliferative and differentiation efficiency of endometrium [175]
NCT02025270	100	Unknown	Al Azhar University, Egypt Stem Cells of	Azoospermic Patients	Bone-Marrow-Derived Mesenchymal Stem Cells	No results posted
NCT02641769	50	Recruiting	Arabia, Amman, Jordan	Non-obstructive Azoospermia	Intratesticular Transplantation of Autologous Stem Cells	No results posted
NCT02414295	1	Completed	Man Clinic for Andrology and male infertilit, Cairo, Egypt	Klinefelter Syndrome Azoospermia	Mesenchymal Stem Cell Injection	No Results Posted
NCT02062931	60	Unknown	Al-Azhar University hospitals, Egypt	Premature Ovarian Failure	Biological: Stem Cell Preparation and Injection	No results posted
NCT02603744	9	Unknown	Royan Institute	Premature Ovarian Failure	Intraovarian Injection of Adipose-Derived Stromal Cells (Adscs)	Intraovarian engrafting of ADSCs were found to be safe and feasible and linked to reduction in FSH level [176]
NCT02204358	30	Unknown	Nanjing University Medical School	Intrauterine Adhesions, Endometrial Dysplasia	Collagen Scaffold Loaded with Autologous Bone Marrow Stem Cells Testicular Injection of Autologous Human Bone Marrow	No results posted

Trial Identifier	Est. # of Subjects	Status	Site	Conditions	Interventions	Outcome of Trial
NCT02041910	60	Unknown	Hesham Saeed Elshaer, El-Rayadh Fertility Centre	Azoospermia	Derived Stem Cells	No results posted
NCT02151890	10	Completed	Al Azhar University, Cairo, Egypt	Premature Ovarian Failure	Biological: Stem Cell	No results posted
NCT02372474	112	Completed	Al Azhar University, Cairo, Egypt	Premature Ovarian Failure	Biological: Stem Cell	No results posted
NCT01742533	40	Unknown	Shenzhen People's Hospital, Shenzhen, Guangdong, China	Premature Ovarian Failure	Biological: Human Umbilical Cord Mesenchymal Stem Cells and Human Cord Blood Mononuclear Cells Drug: Hormone Replacement Therapy	No results posted
NCT03069209	50	Active, not recruiting	Stem Cells Arabia, Amman, Jordan	Premature Ovarian Failure	Biological: Stem Cells	No results posted
NCT00429494	60	Completed	UT MD Anderson Cancer Center, United States	Amenorrhea Premature Ovarian Failure Ovarian Function Insufficiency	Procedure: Hematopoietic Stem Cell Transplantation (Hsct) Drug: Leuprolide Acetate Behavioral: Questionnaire	Phase II trial revealed that Leuprolide could not preserve ovarian function in HSCT patients [177]


Trial Identifier	Est. # of Subjects	Status	Site	Conditions	Interventions	Outcome of Trial
NCT04009473	100	Enrolling by invitation	Multicenter	Ovarian Failure Premature Ovarian Failure	Combination Product: SEGOVA Procedure Includes Stem Cell Therapy, Growth Factor, and Platelet Plasma Rich Therapy	No results posted
NCT02240823	30	Unknown	Odense University Hospital	Erectile Dysfunction After Prostatectomy	Adipose-Derived Stem Cells (ADMSC)	Intracavernous injection of ADMSC is a safe procedure and resulted in improvement of erectile function [178]
NCT02414308	20	Unknown	Man Clinic for Andrology, Male Infertility, and Sexual Dysfunction Man Clinic for Andrology, Male Infertility, and Sexual Dysfunction	Erectile Dysfunction Peyronie' Disease	Adipose Tissue Stem Cell Injection	No results posted
NCT02008799	20	Recruiting	Man Clinic for Andrology, Male Infertility, and Sexual Dysfunction	Azoospermia	Intratesticular Artery Injection of Bone Marrow Stem Cell	No result posted



Aged ovary



Immunomodulatory effect



TNF- α
Anti-inflammatory cytokines
(Zhang et al., 2015; Li et al., 2017)

- Balance between pro-inflammatory and anti-inflammatory cytokines (Yin et al., 2018)
- Balance between macrophages and regulatory T-cells populations (Abumaree et al., 2013; Yin et al., 2018)
- Regulation of oxidative stress (Seok et al., 2020)


Antifibrotic effect




bFGF
Adrenomedullin
HGF
(Figuerola et al., 2012)

- Collagen decrease (Affifi et al., 2013)
- Inhibition of fibroblasts proliferation and extracellular matrix deposition (Wang et al., 2017; He et al., 2018)

STEM CELLS




Folliculogenesis and regulation of GC survival



VEGF
HGF
IGF-1
FGF2
(Uzumcu et al., 2006; Fu et al., 2008)


- Reduction of apoptosis and atresia (Herraiz et al., 2018)
- Regulation of proapoptotic proteins (Liu et al., 2020; Guo et al., 2013)
- Promotion of cell proliferation (Zhou et al., 2013)


Regulation of angiogenesis




VEGF
FGF2
IL-6
PDGF
angionin
(Kinaird et al., 2004; Liang et al., 2017)

- Neoangiogenesis and vasculogenesis (Carrion et al., 2013; Abd-Allah et al., 2013)








STEM CELL THERAPY



Bone Marrow



Umbilical cord



Adipose Tissue



Menstrual Blood

- Stem Cells are collected from Bone Marrow / Umbilical cord / Fat / Menstrual Blood

COLLECTION


PROCESSING

- Blood or Bone Marrow is processed in the laboratory to purify and concentrate the stem cells

- The Stem Cells are reinfused into the patient through intravenous injection

REINFUSION

Main challenges



Stem cell type
and source



Degree of
disease



Stem cell
preparation



Dosage and
Route of
administration



Critical points for selection of stem cell type




- ❖ **Accessibility**
- ❖ **Ethics**
- ❖ **Sterility**
- ❖ **Teratoma formation**
- ❖ **Immune rejection**
- ❖ **Genome stability**
- ❖ **Proliferation and differentiation ability**
- ❖ **Disorder type for stem cell therapy**

Pros and cons of each stem cell type

Criteria	Stem Cell Types				
	Embryonic	Bone marrow-Mesenchymal	Hematopoietic	Umbilical cord blood	Menstrual blood
Plasticity	Pluripotent	Multipotent	Multipotent	Multipotent	Multipotent
Proliferation ability	+++++	+++	+++	++++	++++
Tumor formation (safety consideration)	High	no	no	no	no
Last of cell line	+++++	++	++	+++	+++
Immune rejection (safety consideration)	high	no	no	no	no
Accessibility	Low	Low	Low	Medium	High
Repeatability	Very low	low	low	low	High
Genome Stability(safety consideration)	Instable	Stable	Stable	Stable	Stable
Cost	+++++	+++	+++	+++	+++
Ethical issue	significant	low	low	Very low	Very Low

Main challenges

2



Stem cell type
and source



Degree of
disease




Stem cell
preparation



Dosage and
Route of
administration



Dialogue taking place between the stem cells and the niche



Premature
ovarian failure



Ovarian
insufficiency



Poor Ovarian
Response



Thin
endometrium

Stem cell
therapy

Vaginal
reconstruction

Erectile
dysfunction

Azoospermia
Oligospermia



Autologous stem cell ovarian transplantation to increase reproductive potential in patients who are poor responders


Sonia Herraiz, Ph.D.,^{a,b,c} Mónica Romeu, M.D.,^{c,d} Anna Buigues, B.Sc.,^{a,c,e} Susana Martínez, M.D.,^d César Díaz-García, M.D.,^f Inés Gómez-Seguí, M.D.,^g José Martínez, M.D.,^h Nuria Pellicer, M.D.,^d and Antonio Pellicer, M.D.^{a,c,i}

^a Fundación IVI, ^b IVI-RMA Valencia, ^c Reproductive Medicine Research Group, IIS La Fe, ^d Women's Health Area, ^g Hematology Department, and ^h Radiology Department, La Fe University Hospital; ^e Department of Pediatrics, Obstetrics and Gynecology, University of Valencia, Valencia, Spain; ^f IVI-RMA London, London, United Kingdom; and ⁱ IVI-RMA Rome, Rome, Italy

Improvement of Pregnancy Rate and Live Birth Rate in Poor Ovarian Responders by Intraovarian Administration of Autologous Menstrual Blood Derived- Mesenchymal Stromal Cells: Phase I/II Clinical Trial



Simin Zafardoust¹ • Somaieh Kazemnejad¹ • Maryam Darzi¹ • Mina Fathi-Kazerooni¹ • Hilda Rastegari¹ • Afsaneh Mohammadzadeh¹




born babies using menstrual blood stem cells

Regenerative factor	Study population	Administration method	Main findings	Limitations	Reference
BM-MSC	1 perimenopausal woman (45-year old). AMH 0.4 ng/ml AFC = 1	BM-MSCs into both ovaries <i>via</i> laparoscopy.	-AFC and AMH increased 8 weeks after treatment. -1 live birth.	POR similar to that reported for POI patients without treatment	Gupta et al. (17)
BM-MSC	10 women with idiopathic POI (26–33 years old). AMH <0.1 ng/ml; FSH = 58 mIU/ml	BM-MSCs into both ovaries <i>via</i> laparoscopy.	-Resumption of menses in 20% patients after 3 months. -10% treatment POR. -One pregnancy and a live birth in one patient showing endometrial regeneration.	POR similar to that reported for POI patients without treatment	Edessy et al. (104)
BM-MSC	30 patients with POF (18–40 years old). Baseline characteristics not reported.	Direct laparoscopic infusion into the ovarian stroma and catheterism into the ovarian artery of one side.	-86.7% POF patients improved hormone profile 4 weeks after treatment. -60% showed ovulation. -3 patients underwent IVF. -1 spontaneous pregnancy.	-AFC not reported or compared between ovaries. -IVF outcomes were not reported.	Gabr et al. (105)
BM-MSC	33 patients with idiopathic/other POF/ POI and low ovarian reserves. Baseline characteristics not yet reported.	BM-MSCs into both ovaries <i>via</i> laparoscopy.	Not yet reported	Still ongoing	Al-Hendy et al. (NCT02696889)
BMDSC	20 POI patients (<39 years old). (10 patients included) Baseline characteristics not reported	One ovarian artery by intraarterial catheterism (ASCOT) (6 patients) and stem cells mobilization to peripheral blood by means of GSC-F (4 patients).	-Follicular development in both arms (90–140 days after treatments). -AFC increase in 50% of patients (GSC-F arm) and 66.6% of women (ASCOT arm). -Statistically significant FSH decrease is not observed, although FSH decreased was decreased. -In G-CSF arm: COS initiated in 2/4 women and 1 embryo vitrified. Embryo transfer was performed but pregnancy was not achieved -In the ASCOT arm: COS initiated in 4/6 women, 1 embryo vitrified and transferred, having an ongoing pregnancy. -Menses recovery in 40% of patients and climacteric symptoms decrease in 50% of women.	Still ongoing. Preliminary data from interim analysis reported (106)	Herraiz et al., (NCT03535480)

BM-MSC, bone marrow mesenchymal stem cells; BMDSC, bone marrow derived stem cells; POI, premature ovarian insufficiency; POF, premature ovarian failure; POR, poor ovarian responder; AFC, antral follicle count; AMH, anti-Müllerian hormone; FSH, follicle stimulating hormone; COS, controlled ovarian stimulation; IVF, in vitro fertilization; GSC-F, granulocyte colony-stimulating factor; ASCOT, autologous stem cell ovarian transplantation. Modified from Herraiz et al. (106).

Main challenges

3



Stem cell type
and source




Degree of
disease



Stem cell
preparation



Dosage and
Route of
administration




Critical points to prepare stem cells for cell therapy

Facilities

- Class D
- Class C (preparation)
- Class B (processing)

Permenkes 50 , 2012



Quality Control Process

Materials & reagent
Active material
In process control
Final product



Stem cell purity: Establish sensitive analytical methods to detect cells with undesired characteristics

Microbiological safety: endotoxin, mycoplasma

Karyotyping

HLA


Suitable culture condition

Conservation of Functionality

Regulatory authorities are now demanding application of standardization and safety regulations protocols for cellular products, which include the use of Xeno-free culture media, recombinant growth factors in addition to “Good Manufacturing Practice” (GMP) culture supplies.

Main challenges

4



Stem cell type
and source



Degree of
disease



Stem cell
preparation




Dosage and
Route of
administration



Challenges



- How many cells are needed?
- Are the cells implanted alone?...with a scaffold?
- Are the cells modified?...now a 'gene therapy'?
- What is the proposed therapeutic action?



[Some] More Questions...

- What is the optimal method/route to deliver the product?
- What is the optimal timing for product administration relative to the onset of disease/ injury?
- What happens to the cells *in vivo* following delivery?
- Will repeat administration be needed?
- What is the risk/benefit ratio for the intended patient population?
- What are processes by which stem cells contribute to tissue regeneration *in vivo*
- What time is cell product ready for release to clinic and market?

Essential steps for translation to clinic: bench to bedside pathway for stem cell therapy



More than 95 companies activate on stem cell and cellular therapies whole the world

Solution to short cut the clinical trial pathway

- In 2014, a radical regulatory reform in Japan occurred with the passing of two new laws that **permitted conditional approval** of cell-based treatments following early phase clinical trials on the condition that clinical safety data are provided from at least ten patients.
- These laws allow skipping most of the traditional criteria of clinical trials in what was described as “fast track approvals” and treatments were classified according to risk. To date, the treatments that acquired conditional approval include those targeting; spinal-cord injury, cardiac disease and limb ischemia.

- To fulfill manufacturing requirements, researchers must comply with a vast range of regulations, which can vary greatly between international regulatory agencies such as the FDA and EMA.
- The regulations for regenerative medicine products are largely undefined and standards and guidelines are evolving because the standards for safety, efficacy and consistency have not been fully established.
- To fully accept regenerative medicine therapeutics as novel therapeutic tools, they must outperform current existing treatment(s) and be cost effective.

High cost




Pricing of Approved
Cell Therapy
Products

Final challenge:

Favorite outcome: take on healthy baby





Stem cell research is complicated and rapidly changing. Today's medicine generally tries to support or treat injured tissues and organs, but stem cells may someday simply replace them. Stem cell therapy is considered as like a soldier with a weapon. Only if the soldier (experienced doctor), weapon (technology) and bullets (stem cells) all are in our hand than the fight will turn in our favor.

Thank you
for your
attention



Radin, first born baby using menstrual blood stem cells